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Intervention: Efficacy and Clinical Impact of
CilostazolGianmarco de Donato,1 Francesco Setacci,2 Mariagnese Mele,1 Giovanni Giannace,1
Giuseppe Galzerano,1 and Carlo Setacci,1 Siena, ItalyRestenosis is one of the main complications in patients undergoing coronary or peripheral revas-
cularization procedures and is the leading cause for their long-term failures. Cilostazol is the only
pharmacotherapy that showed an adequate efficacy for preventing restenosis in randomized,
controlled studies after coronary or peripheral revascularization procedures. The present review
sums up the main clinical evidence supporting the use of cilostazol after revascularization inter-
ventions, focusing on all its benefits, warnings, and administration schedules.INTRODUCTION
Restenosis is one of themain complications in patients
undergoing coronary or peripheral revascularization
procedures. It can be considered as a reocclusion pro-
cess of the vascular-treated lumen due to an excessive
proliferation of the target vessel wall. Restenosis is the
leading cause for the long-term failure of revasculari-
zation procedures.1 Clinical impact of restenosis is
well reported in literature, showing a strong correla-
tion with poor clinical outcomes after both cardiac
and peripheral interventions.1,2
Pathogenic mechanisms underlying restenosis
development are still not entirely known, but they
show similar features both at coronary and periph-
eral levels. In patients undergoing a revascularization
intervention, mechanical lesions of the target artery
wall will induce an endothelial irritation, leading to
a complex series of inflammatory responsesnt of Medicine, Surgery and Neuroscience, University of
taly.
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d online: 24 February 2017characterized by thrombotic events, platelet activa-
tion, fibrin deposition, leukocyte migration, together
with extracellular matrix build-up and smooth mus-
cle cell hyperproliferation.3
Variable rates of restenosis after a revasculariza-
tion procedure are observed based on patients and
procedure characteristics. An incidence of about
15e25% after a coronary stent implantation3 and
from 5% to 70% after a peripheral revasculariza-
tion4 can be esteemed.
Until now, there are no authorized drugs for pre-
venting a restenosis after cardiac and peripheral
revascularization procedures; in fact, the only useful
strategy is now represented by medical devices:
drug-eluting stents releasing antiproliferative
drugs.5 Oral antiplatelet aggregation drugs (e.g.,
aspirin, clopidogrel, prasugrel, ticlopidine, and tica-
grelor) should be administered after a cardiac revas-
cularization procedure for preventing the
occurrence of a stent or by-pass reocclusion essen-
tially due to thrombotic events, but they have no
relevant effects on reocclusion phenomena caused
by target vessel restenosis (hyperproliferative
events). In addition, statins have been proposed as
antirestenosis agents; however, adequate clinical
findings are absent and their impact on stent reste-
nosis is still under debate.
Cilostazol is the only pharmacotherapy that
showed an adequate efficacy for preventing resteno-
sis in randomized and controlled studies after coro-
nary and peripheral revascularization procedures.
Fig. 1. Mechanism of action and pharmacological
effects of cilostazol. AMP, adenosine monophosphate;
PDE, phosphodiesterase; cAMP, cyclic adenosine
monophosphate; CXCR4, C-X-C chemokine receptor
type 4; HDL, high-density lipoprotein; HGF, hepatocyte
growth factor; SDF1a, stromal cell-derived factor 1a;
SLX, Sialil-LewisX.
Volume 41, May 2017 Efficacy and clinical impact of cilostazol 301The aim of the present review was to sum up the
main clinical evidence supporting the use of cilosta-
zol after revascularization interventions, focusing
on all its benefits, warnings, and administration
schedules, to provide clinicians with practical infor-
mation for a proper use of the drug.CILOSTAZOL
Cilostazol was launched in Italy in 2008, and it is
indicated for the improvement of the maximal and
pain-free walking distances in patients with inter-
mittent claudication (peripheral arterial diseasee
Fontaine stage II).
Cilostazol is a selective phosphodiesterase III in-
hibitor with known antiplatelet, vasodilative, and
antiproliferative effects on vessel smooth muscle
cells and positive effects on high-density lipoprotein
cholesterol and triglyceride levels. In addition,
several studies evaluated its pharmacological effects
for the prevention of restenosis, suggesting favor-
able effects on reendothelialization mediated by
hepatocyte growth factor6 and endothelial precur-
sor cells,7 as well as on the inhibition of smooth
muscle cell proliferation8 and the inhibition of
leukocyte adhesion to endothelium therefore exert-
ing an anti-inflammatory effect9 (Fig. 1). These
effects may, at least in part, explain the clinical
efficacy of cilostazol in preventing restenosis and
in promoting the long-term outcome of revascular-
ization interventions. In fact, the antiproliferative
effects on smooth muscle cells, the anti-
inflammatory effects, and the endotheliumprotection can counter the complex events underly-
ing restenosis and prevent reocclusion of the vessel.
On the other hand, antiplatelet agents are well
known to reduce fatal or nonfatal cardiovascular
disease events in patients with coronary or periph-
eral artery disease.
Starting from the late 9190s, cilostazol has also
been studied in a large number of randomized,
controlled clinical trialsdmainly carried out in
Asian countries or USAdfor the prevention of reste-
nosis after coronary, carotid, and lower limb
revascularization.CLINICAL EFFICACY
Table I shows the results of the main meta-analysis
on the use of cilostazol after percutaneous coronary
or peripheral revascularization.Coronary RevascularizationStudies that proved the efficacy of cilostazol for
preventing a restenosis and improving the clinical
outcome after percutaneous revascularization
enrolled the following patients: patients with stable
or unstable angina or silent myocardial ischemia,15
patients with acute coronary syndrome,16 diabetic
patients with angina pectoris,17 patients with long
lesions,18 and patients who underwent elective
balloon percutaneous transluminal coronary
angioplasty.19
A meta-analysis including more than 5,000
patients randomized to receive cilostazol plus single
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302 de Donato et al. Annals of Vascular Surgeryor dual antiplatelet treatment versus single or dual
antiplatelet treatment alone, with a follow-up
from 1 to 36 months, has shown the efficacy of cil-
ostazol for preventing angiographic restenosis and
improving the clinical outcome after a stent implan-
tation with or without eluting drugs. These results
suggest a significant reduction of restenosis inci-
dence (40%; P  0.001) and a decreased need
for repeat revascularization (31%; P  0.001).10
Another meta-analysis was carried out to eval-
uate the clinical effects of a cilostazol treatment in
more than 14,000 patients randomized to receive
cilostazol plus a dual antiplatelet treatment versus
dual antiplatelet treatment alone, after a stent
implantation with or without eluting drugs, with a
follow-up from 1 to 25 months. Results show that
the cilostazol treatment has efficiently and signifi-
cantly reduced the incidence of major cardiovascu-
lar events (32%; P < 0.05), the need for repeat
revascularization (43%; P < 0.05), and the onset
of stent thrombosis (37%; P < 0.05).11 Both
studies have confirmed a satisfactory drug safety
profile.
A recent randomized study has also evaluated the
effect of a cilostazol treatment started 6months after
a coronary stent implantation, following the with-
drawal of one of the dual standard antiplatelet treat-
ments, versus patients continuously treated with a
single antiplatelet treatment after the drug with-
drawal. Results show that the cilostazol treatment
has efficiently and significantly reduced the inci-
dence of the study primary end points (death com-
bined score for any cause, myocardial infarction,
stroke, and revascularization intervention) up to
2-year follow-up (39%, P ¼ 0.021)20 (Fig. 2). Of
note, the rate of major or minor bleeding was not
significantly different between the aspirin plus cilos-
tazol and aspirin-only groups.Carotid RevascularizationA recent meta-analysis with a systemic review of
clinical studiesdthat evaluated the effects of a cilos-
tazol treatment after a carotid stent implantation for
the treatment of asymptomatic or symptomatic sten-
osisdincluded 7 controlled trials (only 1 randomized
trial) for a total of 1,297 patients.12 Meta-analysis re-
sults showed a significantly lower in-stent restenosis
rate in the patients treated with cilostazol after a
mean 20-month follow-up: risk 85%, P < 0.001.
Instead, the pooled incidence of infarction, stroke,
and death at 1- and 20-month follow-up suggests a
statistically not significant risk reduction of 28%
and 24% for the cilostazol group, respectively. This
meta-analysis did not show any safety-related drug
Fig. 2. Design and study results from the study by Ueda
et al.20 Interestingly in this study, cilostazol was started
6 months after revascularization (after discontinuation
of thienopyridine), and it was found still effective in
improving the primary end point.
Volume 41, May 2017 Efficacy and clinical impact of cilostazol 303problems, especially for the bleeding incidence.
Notably, most trials were made of observational
type studies in this setting; therefore, the acquisition
of more robust evidence from randomized trials
would be desirable in future.Peripheral RevascularizationAll studies that showed the efficacy of cilostazol for
preventing restenosis and improving the clinical
outcome after lower limb revascularization included
patients with a peripheral arteriopathy (claudicatio
intermittens of critical lower limb ischemia)21e26;
3 studies have focused specifically on hemodialysis
patients, including a total of 840 subjects.27e29
A meta-analysis including 396 patients random-
ized to receive cilostazol plus antiplatelet treatment
versus antiplatelet treatment alone, after a lower
limb revascularization, with a follow-up from 12
to 24 months, has shown that cilostazol has effi-
ciently and significantly reduced the restenosis inci-
dence (20%; P < 0.0001) and the need for repeat
revascularization (17%; P < 0.0001).13
Another meta-analysis including more than
1,500 patientsdenrolled in 2 randomized studies
and 4 prospective observational studiesdtreated
with cilostazol plus antiplatelet treatment versus
standard antiplatelet treatment alone, after a lower
limb revascularization and with a follow-up from
18 to 37 months, has shown that cilostazol has effi-
ciently and significantly reduced restenosis inci-
dence (29%; P < 0,001), decreased limb
amputation (58%; P < 0.001), and increased sur-
vival without any new revascularization procedures
(+36%; P< 0.001).14 Both studies have confirmed a
satisfactory drug safety profile.
In addition, a recent retrospective study carried
out in the United States including as much as
22,954 patients (of which 1,999 treated with cilosta-
zol), who underwent an open or endovascularlower limb revascularization for intermittent claudi-
cation or critical limb ischemia, has confirmed a sig-
nificant reduction of the amputation rate up to 1-
year follow-up in patients treated with cilostazol
versus controlled group (14.8% vs. 24.0%;
P < 0.0001). This effect proved significant both for
open and endovascular revascularization, and it
was substantially more evident in patients treated
with cilostazol before the intervention.30Data from the Most Recent Randomized
Clinical TrialsTable II summarizes methods and results of random-
ized clinical trials published in 2015 and 2016.20,31e35DRUG TOLERABILITY AND
CONTRAINDICATIONS
Generally, cilostazol is a well-tolerated drug; the
most commonly reported adverse events are head-
ache and gastrointestinal disorders, both transitory
and mild-moderate events. Although not validated
by any adequate clinical studies, a starting scaled
titration dosemay improve the drug tolerability. Cil-
ostazol should not be administered in case of severe
renal impairment or moderate-severe hepatic
impairment; pregnancy; bleeding risk (e.g., active
peptic ulceration, recent hemorrhagic stroke,
proliferative diabetic retinopathy, and poorly
controlled hypertension); decompensated conges-
tive heart failure; patients treated concomitantly
with two or more additional antiplatelet or antico-
agulant agents; severe arrhythmias; unstable angina
pectoris, myocardial infarction within the last
6 months, or any coronary intervention in the last
6 months.
In particular, the last 3 contraindications were
introduced in 2013 by the European Medicines
Agency (EMA) following a referral procedure
Table II. Data from the most recent randomized clinical trials
Study Design
Patients
(Centers) Setting
Follow-up,
months
Treatment groups
(Duration) Primary outcome
Primary
outcome
occurrence
(group 1
vs. 2)
Ueda
et al.20
O 514 (1) Stable CAD
or ACS
patients who
received DES
or BMS
implantation
>6 months
before
(after dual
antiplatelet
therapy
suspension)
24 (1) 245 patients.
CIL (100 mg
bid) + A (81e
100 mg/d)
(2) 260 patients. A
(81e100 mg/d;
for 24 months)
All-cause death,
myocardial
infarction,
stroke, or
coronary
or
cerebrovascular
revascularization
13.9% vs.
22.1%,
P ¼ 0.021
Ari
et al.31
O 172 (1) Stable angina
pectoris
patients
scheduled
for PCI
1 (1) 86 patients. CIL
(200 mg) + CLO
(600 mg) + R
(40 mg)
(2) 86 patients. CLO
(600 mg) + R
(40 mg;
pretreatment)
PPMIJ or PPMIN PPMIJ: 21%
vs. 24%,
P ¼ 0.58;
PPMIN: 2.3%
vs. 7%,
P ¼ 0.27
Wang
et al.32
O 153 (1) Non-STEMI
patients who
underwent
PCI
1 (1) 74 patients. A
(100 mg/
day) + CLO (75 mg/
day) + CIL (100 mg
bid)
(2) 79 patients. A
(100 mg/
day) + CLO (75 mg/
day; 30 days)
NA d
Lee
et al.33
B 254 (6) NSTE-ACS
patients
undergoing
percutaneous
coronary
intervention
1 (1) 127 patients. A
(100 mg/
day) + CLO (75 mg/
day) + CIL (100 mg
bid)
(2) 127 patients. A
(100 mg/
day) + CLO (75 mg/
day) (1 month)
MACE* up to
30 days
27.1%
vs. 28.8%,
P ¼ 0.777
Xu
et al.34
O 113 (1) ACS patients
undergoing
PCI
<1 (1) 56 patients. A
(100 mg/
day) + CLO (75 mg/
day) + CIL (100 mg
bid)
(2) 57 patients. A
(100 mg/
day) + CLO (75 mg/
day; 7 days)
Periprocedural
myocardial
infarction up to
24 hr after PCI
32.1%
vs. 47.4%,
P ¼ 0.098
(Continued)
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Table II. Continued
Study Design
Patients
(Centers) Setting
Follow-up,
months
Treatment groups
(Duration) Primary outcome
Primary
outcome
occurrence
(group 1
vs. 2)
Zheng
et al.35
O 127 (1) Patients with
complex lesions
undergoing PCI
12 (1) 61 patients. A
(100 mg/
day) + CLO
(75 mg/day) + CIL
(50 mg bid)
(2) 66 pts. A
(100 mg/
day) + CLO
(75 mg/day;
12 months)
MACE** up to
1 year
1.6% vs.
16.7%,
P ¼ 0.004
A, aspirin; ACS, acute coronary syndrome; B, blinded end point; BMS, bare-metal stent; CAD, coronary artery disease; CIL, cilostazol;
CLO, clopidogrel; DES, drug-eluting stent; MACE, major adverse cardiovascular events (defined as composite of * cardiovascular death,
myocardial infarction [myocardial infarction; spontaneous, or periprocedural], and ischemia driven target vessel revascularization, or
** cardiac death, myocardial infarction, and target lesion revascularization); NSTE: noneST-segment elevation; O, open; PCI,
percutaneous coronary intervention; PPMIJ, periprocedural myocardial injury; PPMIN, periprocedural myocardial infarction; R,
rosuvastatin; STEMI, ST-segment elevation myocardial infarction.
Table III. Coadministration of cilostazol with inhibitors of CYP3A4 and CYP2C19
Drug
Inhibited
cytochrome
Area under the curve in case of co-administration
Change in the
cilostazol doseCilostazol Dehydrocilostazol 4’-trans-hydroxycilostazol
Erythromycin and
similar agents (e.g.,
clarithromycin)
3A4 +72% +6% +119% 50 mg BID
Ketoconazole and
similar agents (e.g.,
itraconazole)
3A4 +117% 15% +87%
Omeprazole 2C19 +22% +68% 36%
Diltiazem 3A4 +44% +4% +43% None
Grapefruit juice
(240 mL)
3A4 d d d
Cilostazol has 2 major metabolites: dehydro cilostazol and a 4’-trans-hydroxy cilostazol, which present antiplatelet activity 4e7 times
higher and about one-fifth compared with cilostazol, respectively.
Volume 41, May 2017 Efficacy and clinical impact of cilostazol 305initiated by the Spanish authority, whose main
concerns focused on reports received of cardiovas-
cular reactions and hemorrhagic reactions and
drug interactions during the first 18 months of mar-
keting in Spain. Thus, after a complete review of the
clinical and safety profile of cilostazol, EMA intro-
duced these new measures to minimize the poten-
tial occurrence of new adverse events. Although
clinical trial data do not substantiate safety concerns
raised from spontaneous adverse drug reactions
reporting, the Committee for Medicinal Products
for Human Use concluded that the risk of bleeding
and some cardiovascular events cannot be excluded
in at-risk patients (e.g., elderly patients withunderlying co-morbidities receiving a high number
of concomitant medications known to interact
with cilostazol).
Prescribers also need to be aware of the risk of
interactions with cilostazol: its dose should be
reduced in patients concurrently taking strong in-
hibitors of CYP3A4 (e.g., ketoconazole, itracona-
zole, and erythromycin) or CYP2C19 enzymes
(e.g., omeprazole; Table III).THERAPEUTIC SCHEME
Cilostazol should be administered at a dose of
100 mg twice a day (the dose should be reduced to
306 de Donato et al. Annals of Vascular Surgery50 mg twice a day in patients receiving medicines
that strongly inhibit cytochromes).36
In clinical trials, after a percutaneous coronary
revascularization, the treatment was generally
started the day after the intervention for a period
of 12e24 months. Interestingly, the scheme of a
recent study by Ueda et al.20 provided a cilostazol
treatment starting from 6 months after revasculari-
zation in patients who had withdrawn from one of
the standard dual antiplatelet treatments adminis-
tered (Fig. 2). This scheme provides more drug
safety (no infringement of contraindications) and
also significant long-term clinical outcomes.
In clinical trials, after a peripheral revasculariza-
tion, the treatment was generally started the day af-
ter the intervention for a period up to 3 years. In
high bleeding risk patients, it could be useful starting
the treatment after the withdrawal of one drug of
the standard dual antiplatelet treatment adminis-
tered (at least 1month of dual antiplatelet treatment
after an intravascular intervention according to the
guidelines).37CONCLUSIONS
Cilostazol efficiently prevents restenosis by promot-
ing reendothelialization and by inhibiting smooth
muscle cell proliferation and leukocyte adhesion to
endothelium. Until now, cilostazol is the only phar-
macotherapy that showed an adequate efficacy for
preventing restenosis in randomized, controlled
studies after coronary, carotid, or lower limb revas-
cularization. These studies also show a significant
reduction of repeat revascularization and cardiovas-
cular events, with no increase of bleeding risk. Cilos-
tazol should be administered at a dose of 100 mg
twice a day, in a long-term regimen. To optimize
the drug benefit/risk profile, it might be useful start-
ing the treatment after the withdrawal of one of the
standard postoperative dual antiplatelet treatment
and waiting for 6 months after the coronary revas-
cularization procedure.REFERENCES
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